Instem plc, together with its subsidiaries, provides information technology applications to the life sciences healthcare market worldwide.
Price History & Performance
|Historical stock prices|
|Current Share Price||UK£8.30|
|52 Week High||UK£4.21|
|52 Week Low||UK£9.10|
|1 Month Change||-7.00%|
|3 Month Change||11.41%|
|1 Year Change||82.42%|
|3 Year Change||184.25%|
|5 Year Change||175.29%|
|Change since IPO||348.65%|
Recent News & Updates
Instem plc's (LON:INS) Intrinsic Value Is Potentially 44% Above Its Share Price
Does the September share price for Instem plc ( LON:INS ) reflect what it's really worth? Today, we will estimate the...
Is Instem plc's (LON:INS) Recent Stock Performance Influenced By Its Fundamentals In Any Way?
Instem's (LON:INS) stock is up by a considerable 15% over the past three months. As most would know, fundamentals are...
|INS||GB Healthcare Services||GB Market|
Return vs Industry: INS exceeded the UK Healthcare Services industry which returned 42% over the past year.
Return vs Market: INS exceeded the UK Market which returned 24.7% over the past year.
Stable Share Price: INS is not significantly more volatile than the rest of UK stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: INS's weekly volatility (4%) has been stable over the past year.
About the Company
Instem plc, together with its subsidiaries, provides information technology applications to the life sciences healthcare market worldwide. The company offers solutions for data collection, management, and analysis to meet the needs of life science and healthcare organizations for data-driven decision making. Its solutions include ALPHADAS, an eSource EDC system for early phase clinical trials; BioRails for discovery data management; Comet Assay IV, a live video imaging system for reproducible comet slide scoring; and Cyto Study Manager, a data acquisition and reporting solution.
Instem Fundamentals Summary
|INS fundamental statistics|
Is INS overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|INS income statement (TTM)|
|Cost of Revenue||UK£20.00m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||0.077|
|Net Profit Margin||5.02%|
How did INS perform over the long term?See historical performance and comparison
Is Instem undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: INS (£8.3) is trading below our estimate of fair value (£14.71)
Significantly Below Fair Value: INS is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: INS is poor value based on its PE Ratio (108x) compared to the European Healthcare Services industry average (56.4x).
PE vs Market: INS is poor value based on its PE Ratio (108x) compared to the UK market (21.2x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate INS's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: INS's PB Ratio (4.3x) is in line with the GB Healthcare Services industry average.
How is Instem forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual revenue growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if INS's forecast earnings growth is above the savings rate (0.9%).
Earnings vs Market: Insufficient data to determine if INS's earnings are forecast to grow faster than the UK market
High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: INS's revenue (22.7% per year) is forecast to grow faster than the UK market (5% per year).
High Growth Revenue: INS's revenue (22.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: INS's Return on Equity is forecast to be low in 3 years time (15.3%).
How has Instem performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: INS has a large one-off loss of £1.4M impacting its June 30 2021 financial results.
Growing Profit Margin: INS's current net profit margins (5%) are higher than last year (1.2%).
Past Earnings Growth Analysis
Earnings Trend: INS has become profitable over the past 5 years, growing earnings by 20.9% per year.
Accelerating Growth: INS's earnings growth over the past year (403.2%) exceeds its 5-year average (20.9% per year).
Earnings vs Industry: INS earnings growth over the past year (403.2%) exceeded the Healthcare Services industry 35.8%.
Return on Equity
High ROE: INS's Return on Equity (4%) is considered low.
How is Instem's financial position?
Financial Position Analysis
Short Term Liabilities: INS's short term assets (£30.8M) exceed its short term liabilities (£26.7M).
Long Term Liabilities: INS's short term assets (£30.8M) exceed its long term liabilities (£7.5M).
Debt to Equity History and Analysis
Debt Level: INS is debt free.
Reducing Debt: INS currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Debt Coverage: INS has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: INS has no debt, therefore coverage of interest payments is not a concern.
What is Instem current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate INS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate INS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if INS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if INS's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of INS's dividend in 3 years as they are not forecast to pay a notable one for the UK market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Phil Reason (59 yo)
Mr. Phil J. Reason serves as the Chief Executive Officer of Instem LSS Limited, Instem Associates Limited and Instem plc (Instem Life Science Systems plc). Mr. Reason is an experienced chief executive who...
CEO Compensation Analysis
Compensation vs Market: Phil's total compensation ($USD380.44K) is below average for companies of similar size in the UK market ($USD573.07K).
Compensation vs Earnings: Phil's compensation has been consistent with company performance over the past year.
Experienced Management: INS's management team is considered experienced (3.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: INS insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 8.3%.
Instem plc's employee growth, exchange listings and data sources
- Name: Instem plc
- Ticker: INS
- Exchange: AIM
- Founded: 1969
- Industry: Health Care Technology
- Sector: Healthcare
- Market Cap: UK£184.176m
- Shares outstanding: 22.19m
- Website: https://www.instem.com
Number of Employees
- Instem plc
- Diamond Way
- Stone Business Park
- ST15 0SD
- United Kingdom
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/26 21:22|
|End of Day Share Price||2021/10/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.